Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
Related news for (NVAX)
- Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
- Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
- Novavax Announces Progress on Sanofi Agreement
- Novavax’s Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
- Novavax Announces Convertible Debt Refinancing